Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. (Q35684850)
Jump to navigation
Jump to search
scientific article published on 3 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. |
scientific article published on 3 July 2015 |
Statements
Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study (English)
Ian Pearce
Sanjiv Banerjee
Ben J L Burton
Louise Downey
Richard P Gale
Sergio Pagliarini
Jignesh Patel
Sobha Sivaprasad
Chris Andrews
Christopher Brittain
James Warburton
RELIGHT Study Group